We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Takhzyro

News List

Shire's Takhzyro scores EU approval in rare genetic disorder hereditary angioedema pharmafile
December 04, 2018
Shire has announced that it has secured European approval for its subcutaneous injection Takhzyro (lanadelumab) for the routine prevention of attacks as a result of hereditary angioedema (HAE)...
Shire receives USFDA nod for TAKHZYRO biospectrumasia
August 28, 2018
TAKHZYRO is the only monoclonal antibody (mAb) that provides targeted inhibition of plasma kallikrein, an enzyme which is chronically uncontrolled in people with hereditary angioedema, to help prevent attacks
Shire eyes blockbuster sales with 'best-in-class' HAE drug Takhzyro fiercepharma
August 27, 2018
Jefferies analyst David Steinberg predicts Shire's Takhzyro could hit $1.8 billion in peak sales.